Gene and Cell Therapy Workflows
Gene and cell therapies have provided new modalities for treating and potentially curing diseases previously beyond the reach of traditional drug methodologies. The goal of gene therapies is to modify the underlying genetic cause of a disease, while cell therapies involve the introduction or transplantation of human cells to repair or replace damaged tissues. There is a diverse range of therapeutic approaches within the crowded gene and cell therapy space and an even broader set of challenges regarding their development, safety, biomanufacturing, and cost.
Access One-of-a-Kind Gene and Cell Therapy Expertise
At Eurofins Discovery, our expertise in developing various nucleic acid therapeutics, viral vectors, and different cell therapies has given us a thorough understanding of therapeutic candidate design, reagent and assay development, and screening workflows to help you achieve IND approval. Explore our innovative gene therapeutic development and cell therapy development approaches with clearly defined workflows and proven scientific expertise that will put your biotherapeutics on the best path to the clinic.
AAV and other Viral Vector Workflows for Gene Therapies
Adeno-associated viruses (AAVs) are powerful gene therapy vectors for delivering therapeutic genes into target cells. AAV workflows involve the design, production, purification, and delivery of an AAV vector that carries a therapeutic gene. These workflows help ensure a gene therapy candidate’s safe, effective, compliant, and standardized delivery, maximizing the potential for curing a genetic disease.
Cell Therapy Services
The isolation, characterization and expansion of specific immune cells and ensuring they are safe, pure, and functional are essential for cell therapy development. These workflows help maintain and secure the quality and consistency of cell-based therapies, assuring compliance with regulatory guidelines and reliable clinical outcomes. At Eurofins Discovery, our cell therapy experts cover the full spectrum of needs from early discovery through manufacturing to ensure your program has support for the development and scalability of innovative therapies.
